A phase II trial to assess the safety and immunological activity of TroVax plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma. The SKOPOS trial
A phase II trial to assess the safety and immunological activity of TroVax plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma. The SKOPOS trial
Malignant pleural mesothelioma (MPM) is an incurable
and fatal malignancy of the pleural membranes. No surgical
approach, alone or as part of a multimodality strategy, has been
shown to prolong survival and pemetrexed cisplatin is now seen as
the chemotherapy standard of care in the UK. However it is clear
that new therapeutic strategies are urgently needed for MPM.
Immunotherapy is potential new treatment approach to be
considered in MPM, as the disease has been shown to respond to
various immunotherapeutic strategies tested in animal models and
early phase clinical trials. TroVax® consists of a highly attenuated
vaccinia virus containing the human TAA 5T4 glycoprotein gene
under regulatory control of a modified VV promoter, mH5. Velindre
NHS Trust and the Wales Cancer Trials Unit in Cardiff, UK have
developed a clinical trial to evaluate whether TroVax® is active in
the treatment of MPM.
S82
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lester, J.F.
420d7852-31bb-4b9a-8a35-e0d4c66d14e4
Casbard, A.
a5459533-54d6-4ca2-b746-8518afa0c914
Roberts, K.
b8b09bab-b14d-4d97-92d6-521508670132
Tabi, Z.
ea45ede8-1a6c-4aa5-92d7-de5a9b176d15
2014
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lester, J.F.
420d7852-31bb-4b9a-8a35-e0d4c66d14e4
Casbard, A.
a5459533-54d6-4ca2-b746-8518afa0c914
Roberts, K.
b8b09bab-b14d-4d97-92d6-521508670132
Tabi, Z.
ea45ede8-1a6c-4aa5-92d7-de5a9b176d15
Griffiths, Gareth, Lester, J.F., Casbard, A., Roberts, K. and Tabi, Z.
(2014)
A phase II trial to assess the safety and immunological activity of TroVax plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma. The SKOPOS trial.
.
Record type:
Conference or Workshop Item
(Poster)
Abstract
Malignant pleural mesothelioma (MPM) is an incurable
and fatal malignancy of the pleural membranes. No surgical
approach, alone or as part of a multimodality strategy, has been
shown to prolong survival and pemetrexed cisplatin is now seen as
the chemotherapy standard of care in the UK. However it is clear
that new therapeutic strategies are urgently needed for MPM.
Immunotherapy is potential new treatment approach to be
considered in MPM, as the disease has been shown to respond to
various immunotherapeutic strategies tested in animal models and
early phase clinical trials. TroVax® consists of a highly attenuated
vaccinia virus containing the human TAA 5T4 glycoprotein gene
under regulatory control of a modified VV promoter, mH5. Velindre
NHS Trust and the Wales Cancer Trials Unit in Cardiff, UK have
developed a clinical trial to evaluate whether TroVax® is active in
the treatment of MPM.
This record has no associated files available for download.
More information
Published date: 2014
Identifiers
Local EPrints ID: 413100
URI: http://eprints.soton.ac.uk/id/eprint/413100
PURE UUID: 5623bc49-270a-46ba-b831-45133db73c52
Catalogue record
Date deposited: 15 Aug 2017 16:30
Last modified: 19 Mar 2024 02:46
Export record
Contributors
Author:
J.F. Lester
Author:
A. Casbard
Author:
K. Roberts
Author:
Z. Tabi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
